Systemic lupus erythematosus

A7.06 Low-dose IL-2 therapy in refractory sle: Insights from a phase I/IIA clinical trial
JY Humrich, C von Spee-Mayer, E Siegert, M Bertolo, D Abdirama, A Rose, P Enghard, A Radbruch, GR Burmester, G Riemekasten

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A58; DOI: 10.1136/annrheumdis-2016-209124.137
A2.01 Increased soluble CD72 in systemic lupus erythematosus: A potential biomarker for disease activity and lupus nephritis
Z Vadasz, E Toubi

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A15-A16; DOI: 10.1136/annrheumdis-2016-209124.37
A2.01 The expansion of CD25^highIL-10^highFOXP3^high B regulatory cells is in association with sle disease activity
E Toubi, Z Vadasz

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A15; DOI: 10.1136/annrheumdis-2016-209124.36
A2.09 Longitudinal EBV antibody profiling in sle patients reveals patients with lupus nephritis
HM van Dongen, N Masoumi, M Tsang-A-Sjoe, JM Middeldorp, AE Voskuyl, DM Pegtel

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A18-A19; DOI: 10.1136/annrheumdis-2016-209124.44
A2.17 Detection of autoantigen-specific CD4⁺ T cells associated with systemic lupus erythematosus
D Abdirama, P Enghard, S Tesch, A Radbruch, GR Burmester, G Riemekasten

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A22; DOI: 10.1136/annrheumdis-2016-209124.52
A2.21 The increase of circulating CD4⁺ T-cells with effector phenotype in patients with systemic lupus erythematosus may be reverted after belimumab therapy
S Piantoni, M Scarsi, L Andreoli, F Dall’Ara, A Zanola, A Tincani, P Airò

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A23-A24; DOI: 10.1136/annrheumdis-2016-209124.56
Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty?
Frédéric A Houssiau, Andrea Doria

Annals of the Rheumatic Diseases Feb 2016, 75 (2) 321-322; DOI: 10.1136/annrheumdis-2015-208312
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
D A Isenberg, M Petri, K Kalunian, Y Tanaka, M B Urowitz, R W Hoffman, M Morgan-Cox, N Iikuni, M Silk, D J Wallace

Annals of the Rheumatic Diseases Feb 2016, 75 (2) 323-331; DOI: 10.1136/annrheumdis-2015-207653
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
J T Merrill, R F van Vollenhoven, J P Buyon, R A Furie, W Stohl, M Morgan-Cox, C Dickson, P W Anderson, C Lee, P-Y Berclaz, T Dörner

Annals of the Rheumatic Diseases Feb 2016, 75 (2) 332-340; DOI: 10.1136/annrheumdis-2015-207654
Further thoughts about the ILLUMINATE studies of tabalumab in SLE
David Isenberg

Annals of the Rheumatic Diseases Feb 2016, 75 (2) e11; DOI: 10.1136/annrheumdis-2015-208709

Main menu

Systemic lupus erythematosus

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Systemic lupus erythematosus

Pages